The aberrant expression of PGRMC1 at both transcript and protein levels have been reported in multiple types of cancer, including breast (Neubauer et al., 2013; Li et al., 2019), ovarian (Peluso et al., 2008; Mir et al., 2012), as well as head and neck cancer (Zhao and Ruan, 2019). Here, PGRMC1 is linked to head and neck cancer.